Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Novocure (NVCR) will present real-world data at ESMO 2024 showing improved survival outcomes for newly diagnosed glioblastoma (ndGBM) patients with increased use of Tumor Treating Fields (TTFields) therapy. The analysis suggests higher TTFields device usage is significantly associated with better survival in a broad ndGBM patient population.
The presentation, titled 'Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US', will be displayed as Poster #459 on September 16. Novocure has also sponsored an ESMO Colloquium on the role of alternating electric fields in treating advanced non-small cell lung cancer, scheduled for September 16.
Novocure (NVCR) presenterà dati del mondo reale all'ESMO 2024, mostrando miglioramenti nei risultati di sopravvivenza per i pazienti recentemente diagnosticati con glioblastoma (ndGBM) grazie all'aumento dell'uso della terapia con Campi Elettrici Tumorali (TTFields). L'analisi suggerisce che un utilizzo più elevato del dispositivo TTFields è significativamente associato a una migliore sopravvivenza in un'ampia popolazione di pazienti ndGBM.
La presentazione, intitolata 'Associazione tra l'uso del dispositivo per Campi Elettrici Tumorali e la sopravvivenza nei GBM recentemente diagnosticati: un'analisi reale dei pazienti negli Stati Uniti', sarà esposta come Poster #459 il 16 settembre. Novocure ha anche sponsorizzato un Colloquio ESMO sul ruolo dei campi elettrici alternati nel trattamento del cancro polmonare non a piccole cellule avanzato, previsto per il 16 settembre.
Novocure (NVCR) presentará datos del mundo real en ESMO 2024, mostrando mejores resultados de supervivencia para pacientes recién diagnosticados con glioblastoma (ndGBM) con un aumento en el uso de la terapia con Campos Eléctricos Tumorales (TTFields). El análisis sugiere que un mayor uso del dispositivo TTFields está significativamente asociado con una mejor supervivencia en una amplia población de pacientes ndGBM.
La presentación, titulada 'Asociación del uso del dispositivo de Campos Eléctricos Tumorales con la supervivencia en GBM recién diagnosticados: un análisis del mundo real de pacientes en EE. UU.', se exhibirá como Póster #459 el 16 de septiembre. Novocure también ha patrocinado un Coloquio ESMO sobre el papel de los campos eléctricos alternos en el tratamiento del cáncer de pulmón no microcítico avanzado, programado para el 16 de septiembre.
Novocure (NVCR)는 ESMO 2024에서 실제 데이터를 발표하여 최근 진단된 교모세포종(ndGBM) 환자들이 종양 치료 전기장(TTFields) 치료의 사용 증가로 생존 결과가 개선되었음을 보여줄 것입니다. 분석에 따르면 TTFields 장치의 사용 증가가 광범위한 ndGBM 환자 집단에서 더 나은 생존과 유의미한 연관이 있음을 시사합니다.
‘최근 진단된 GBM에서 종양 치료 전기장 장치 사용과 생존의 연관성: 미국 환자에 대한 실제 분석’이라는 제목의 이 발표는 9월 16일 포스터 #459로 전시됩니다. Novocure는 또한 9월 16일에 예정된 비소세포 폐암의 치료에서 교대 전기장의 역할에 관한 ESMO 콜로퀴엄을 후원했습니다.
Novocure (NVCR) présentera des données du monde réel lors de l'ESMO 2024, montrant une amélioration des résultats de survie pour les patients récemment diagnostiqués avec un glioblastome (ndGBM) grâce à une utilisation accrue de la thérapie par Champs Électriques Tumoraux (TTFields). L'analyse suggère qu'une utilisation plus élevée du dispositif TTFields est significativement associée à une meilleure survie dans une large population de patients ndGBM.
La présentation, intitulée 'Association de l'utilisation du dispositif de Champs Électriques Tumoraux avec la survie dans les GBM nouvellement diagnostiqués : une analyse du monde réel des patients aux États-Unis', sera affichée comme Poster #459 le 16 septembre. Novocure a également parrainé un colloque ESMO sur le rôle des champs électriques alternés dans le traitement du cancer du poumon non à petites cellules avancé, prévu pour le 16 septembre.
Novocure (NVCR) wird auf dem ESMO 2024 Realdaten präsentieren, die verbesserte Überlebensraten für neu diagnostizierte Glioblastom-Patienten (ndGBM) zeigen, die eine erhöhte Anwendung der Therapie mit Tumorbehandlungsfeldern (TTFields) aufweisen. Die Analyse deutet darauf hin, dass eine höhere Nutzung des TTFields-Geräts signifikant mit einer besseren Überlebensrate in einer breiten ndGBM-Patientenpopulation assoziiert ist.
Die Präsentation mit dem Titel 'Assoziation der Nutzung des Tumorbehandlungsfeldgeräts mit dem Überleben bei neu diagnostiziertem GBM: Eine reale Analyse von Patienten in den USA' wird am 16. September als Poster #459 gezeigt. Novocure hat auch ein ESMO-Kolloquium zum Thema der alternierenden elektrischen Felder in der Behandlung von fortgeschrittenem nicht-kleinzelligem Lungenkrebs gesponsert, das für den 16. September geplant ist.
- None.
- None.
ROOT,
The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients.
Novocure’s ESMO 2024 Data Presentation Details:
Poster #459: Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US
Authors: Jennifer M. Connelly, Department of Neurology, Medical College of
Date: Monday, September 16
Abstracts are available on the ESMO website, esmo.org/meeting-calendar/esmo-congress-2024/programme.
Novocure has also sponsored an ESMO Colloquium, The Role of Alternating Electric Fields in the Therapeutic Management of Patients with Advanced Non-Small Cell Lung Cancer, which will be held Monday, September 16, 13:00 - 14:30 CEST, in the Oviedo Auditorium, Hall 3.
About Tumor Treating Fields
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909217183/en/
Investors:
Ingrid Goldberg
investorinfo@novocure.com
Media:
Catherine Falcetti
media@novocure.com
Source: Novocure
FAQ
What will Novocure (NVCR) present at ESMO 2024?
When and where is ESMO 2024 taking place?
What is the title of Novocure's (NVCR) poster presentation at ESMO 2024?
What additional event has Novocure (NVCR) sponsored at ESMO 2024?
When is Novocure's (NVCR) sponsored colloquium scheduled at ESMO 2024?
